The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 20, 2016
Filed:
Oct. 24, 2012
Applicant:
The Brigham and Women's Hospital, Inc., Boston, MA (US);
Inventors:
Raphael Bueno, Brookline, MA (US);
David Sugarbaker, Milton, MA (US);
Assignee:
THE BRIGHAM AND WOMEN'S HOSPITAL, INC., Boston, MA (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/565 (2006.01); A61K 31/519 (2006.01); A61K 33/24 (2006.01); A61K 31/282 (2006.01); G01N 33/68 (2006.01); C12Q 1/68 (2006.01); A61K 31/566 (2006.01); A61K 31/567 (2006.01); A61K 45/06 (2006.01); A61K 31/555 (2006.01); A61K 31/56 (2006.01); A61K 31/58 (2006.01); G01N 33/574 (2006.01); G06F 19/00 (2011.01);
U.S. Cl.
CPC ...
A61K 31/565 (2013.01); A61K 31/282 (2013.01); A61K 31/519 (2013.01); A61K 31/555 (2013.01); A61K 31/56 (2013.01); A61K 31/566 (2013.01); A61K 31/567 (2013.01); A61K 31/58 (2013.01); A61K 33/24 (2013.01); A61K 45/06 (2013.01); C12Q 1/686 (2013.01); C12Q 1/6886 (2013.01); G01N 33/57407 (2013.01); G01N 33/6872 (2013.01); G06F 19/34 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01);
Abstract
The present invention provides that Ras-like, estrogen-regulated, growth inhibitor (RERG) is a malignant mesothelioma biomarker of clinical course and treatment sensitivity and, itself a target for mesothelioma treatment. A low RERG level in a mesothelioma subject indicates poor prognosis. Analyzing RERG expression level along can help mesothelioma patients make treatment choices. Furthermore, mesothelioma can be treated by modulating RERG activity, for example, with treatment with estrogen or estrogen-like agents.